mechanism of glp-1 receptor agonists Frontiers Therapeutic Potential of GLP-1 Receptor

As both IBD and PD have compromised intestinal barrier functions, DJ-1 deficiency promotes cytokine-mediated inflammation (IL-1, IL-6, TNF, and TGFB1) and apoptosis of intestinal epithelial cells via a p53-dependent mechanism in vitro , in ex vivo colonic sacs, and in vivo (van IJzendoorn and Derkinderen, 2019

Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)

Research has documented BPC-157s neuroprotective and neuroregenerative effects across multiple central and peripheral nervous system injury models

Verdict at a Glance Orforglipron represents a potential paradigm shift as the first oral non-peptide GLP-1 agonist without fasting restrictions, and it demonstrated superiority over oral semaglutide in the head-to-head ACHIEVE-3 trial for both HbA1c and weight loss